We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Weekly Chemotherapy of 5‐Fluorouracil plus Cisplatin Concurrent with Radiotherapy for Esophageal Squamous Cell Carcinoma Patients with Postoperative Locoregional Recurrence: Results from a Phase II Study.
- Authors
Chen, Baoqing; Li, Qiwen; Li, Qiaoqiao; Qiu, Bo; Xi, Mian; Liu, Mengzhong; Hu, Yonghong; Zhu, Yujia
- Abstract
Lessons Learned: Weekly treatment with 5‐fluorouracil and cisplatin, concurrent with radiotherapy, achieved promising response rates in patients with postoperative recurrent esophageal squamous cell carcinoma.Superior toxicity results were also found. Background: Concurrent chemoradiotherapy (CCRT) is one of the treatment strategies for patients with esophageal squamous cell carcinoma (ESCC) with postoperative locoregional recurrence. However, the once every 3 weeks chemotherapy regimen causes a high incidence of toxicity. The aim of this study was to evaluate the efficacy and toxicity of weekly 5‐fluorouracil (5‐FU) and cisplatin concurrent with radiotherapy in postoperative locoregional recurrent ESCC. Materials and Methods: Patients received four weekly chemotherapy cycles of cisplatin (25 mg/m2, day 1) plus 5‐FU (1,176 mg/m2, day 1–3), and concurrent with radiotherapy (50.4–60 Gy). The primary endpoint was objective response rate (ORR). Secondary objectives were toxicity, disease control rate (DCR), progression‐free survival (PFS), and overall survival (OS). Results: Between January 2013 and December 2015, 48 patients were enrolled. The ORR was 68.8% (12 patients with complete response, 21 patients with partial response), with DCR 68.8%. No treatment‐related grade 4 adverse events occurred. Grade 3 hematologic toxicities were observed in eight (17%) patients. Grade 3 vomiting or esophagitis occurred in four (8%) patients each. The median PFS and OS were 13.94 months (95% confidence interval [CI], 0.75–51.05) and 27.43 months (95% CI, 5.278–49.58; Fig. 1). Conclusion: Weekly 5‐FU and cisplatin concurrent with radiotherapy achieved a promising response rate and improved toxicity in patients with postoperative locoregional recurrent ESCC.
- Subjects
CANCER relapse; CISPLATIN; CLINICAL trials; CONFIDENCE intervals; CLINICAL drug trials; DRUG toxicity; ESOPHAGEAL cancer; FLUOROURACIL; SQUAMOUS cell carcinoma; TREATMENT effectiveness; DESCRIPTIVE statistics; CHEMORADIOTHERAPY
- Publication
Oncologist, 2020, Vol 25, Issue 4, p308
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2019-0931